PUBLIC COMPANY
save$AUTLAutolus Therapeutics plc
$AUTLLondon, GBupdated 21d ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
- phase1Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
- phase2Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
- phase1A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- phase1Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
- —Expanded Access Program for OOS Obe-cel
- phase2Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
- phase2Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
🐶 Hiring Signal
News
- Kolon TissueGene cuts 37 US staffers after Phase 3 failFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffersAs always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 8mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that